1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About

Elastrin Therapeutics Inc.

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2017

Location

SC US

Primary Industry

Biotechnology

About

Based in South, Carolina, US, and founded in 2017, Elastrin Therapeutics Inc. operates as a biotechnology company that offers a platform that targets and restores degraded elastin which removes harmful calcification for stiff arteries. The company's CEO is Matthias Breugelmans. The company is composed of bioengineers that develop a technology that restores hardened and damaged arteries & tissue by targeting the elastic fibers. It also targets calcified heart valves, diabetes complications, and COPD. The technology improves the efficacy of drugs and eliminates side-effects by combining particle design with elastin targeting.
Current Investors
KIZOO Technology Ventures, South Carolina Research Authority, Starbloom Capital

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Cardiology
Website
www.elastrin-therapeutics.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.